# Lymphocyte Count, ATG Dose and Incidence and Severity of GVHD in Pediatric Recipients of HSCT

> **NCT04869254** · — · COMPLETED · sponsor: **IRCCS Burlo Garofolo** · enrollment: 102 (actual)

## Conditions studied

- Hematopoietic Stem Cell Transplantation

## Interventions

- **OTHER:** Lower lymphocyte/ATG ratio
- **OTHER:** Higher lymphocyte/ATG ratio

## Key facts

- **NCT ID:** NCT04869254
- **Lead sponsor:** IRCCS Burlo Garofolo
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2000-01-01
- **Primary completion:** 2018-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2021-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04869254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04869254, "Lymphocyte Count, ATG Dose and Incidence and Severity of GVHD in Pediatric Recipients of HSCT". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04869254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*